Eugene, OR 的 子宮內膜癌 臨床試驗
8 項針對 子宮內膜癌 的研究正在 Eugene（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
招募中3 期
- Oncology Associates of Oregon, P.C. ( Site 8005), Eugene
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
招募中3 期
- Willamette Valley Cancer Institute and Research Center - Eugene, Eugene
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
招募中3 期
- Research Site, Eugene
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
招募中1/2 期
- USOR Oncology Associates of Oregon, P.C., Eugene
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
招募中3 期
- Research Site, Eugene
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
招募中2 期
- 517, Eugene
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
招募中2 期
- Oncology Associates of Oregon, P.C., Eugene
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
招募中2/3 期
- Oncology Associates of Oregon, Eugene
其他城市的 子宮內膜癌 試驗
- Houston, TX68 項研究
- New York City, NY52 項研究
- Boston, MA50 項研究
- Arlington, VA39 項研究
- Nashville, TN38 項研究
- Los Angeles, CA34 項研究
- St. Louis, MO29 項研究
- Philadelphia, PA28 項研究
- San Antonio, TX27 項研究
- Chicago, IL25 項研究
- Columbus, OH25 項研究
- Queens, NY25 項研究
Eugene 的其他研究
- 非小細胞肺癌13 項研究
- 卵巢癌9 項研究
- 乳癌7 項研究
- 慢性淋巴性白血病6 項研究
- 多發性骨髓瘤6 項研究
- 轉移性癌症6 項研究
- 癌症（所有類型）6 項研究
- 藥物使用與成癮5 項研究
- 肺癌5 項研究
- 黃斑部病變5 項研究
- 肥胖症4 項研究
- 前列腺癌3 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。